NC
BOLD

Nexthera Capital’s Audentes Therapeutics, Inc BOLD Stock Holding History

Nexthera Capital’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$11.1M Buy
294,013
+43,393
+17% +$1.67M 9.27% 3
2019
Q1 		$9.78M Sell
250,620
-513,573
-67% -$14.7M 11.87% 1
2018
Q4 		$16.3M Buy
764,193
+223,021
+41% +$5.75M 6.72% 6
2018
Q3 		$21.4M Buy
541,172
+299,672
+124% +$11.2M 4.11% 8
2018
Q2 		$9.23M Buy
+241,500
New +$8.94M 1.43% 20

Other funds holding BOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nexthera Capital's BOLD Position: Q2 2019 in Review

Nexthera Capital increased its Audentes Therapeutics, Inc (BOLD) stake by 17% in Q2 2019, buying an estimated $1.67M and bringing the position to 294,013 shares worth $11.1M. The position accounts for 9.27% of the portfolio, ranked #3.

Nexthera Capital first reported a position in BOLD in Q2 2018 and has held it in 5 quarters since. The position peaked at $21.4M in Q3 2018. 147 funds tracked by Wall St. Rank hold BOLD as of Q2 2019.

  • Nexthera Capital held 294,013 shares of Audentes Therapeutics, Inc worth $11.1M as of Q2 2019.
  • Nexthera Capital bought 43,393 Audentes Therapeutics, Inc shares in Q2 2019, an estimated $1.67M.
  • Audentes Therapeutics, Inc made up 9.27% of Nexthera Capital's portfolio in Q2 2019, its #3 holding.
  • Nexthera Capital first reported a position in Audentes Therapeutics, Inc in Q2 2018 and has held it in 5 quarters since.
  • Nexthera Capital's Audentes Therapeutics, Inc position peaked at $21.4M in Q3 2018.
  • 147 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q2 2019.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.